The Emerging Role and Clinical Significance of PI3K-Akt-mTOR in Rhabdomyosarcoma

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Rhabdomyosarcoma (RMS) is a prevalent soft tissue sarcoma in children and young adults.
• Embryonal RMS (eRMS) has a better prognosis than the aggressive alveolar RMS (aRMS).
• Hyperactivation of the PI3K-Akt-mTOR pathway is common in RMS and linked to poor outcomes.

Purpose of the Study:

• To review therapeutic strategies targeting the PI3K-Akt-mTOR pathway in Rhabdomyosarcoma.
• To explore novel approaches for improving stagnant survival rates in RMS patients.
• To highlight the pathway's critical role in RMS pathogenesis and treatment resistance.

Main Methods:

• Literature review of therapeutic approaches targeting the PI3K-Akt-mTOR pathway.
• Discussion of specific inhibitors (PI3K, Akt) and combination therapies.
• Exploration of dietary supplements (curcumin) and repurposed drugs (chloroquine) for apoptosis induction.

Main Results:

• The PI3K-Akt-mTOR pathway is a key driver of RMS cell proliferation, survival, and therapy resistance.
• Targeted inhibitors and combination therapies show potential for enhancing treatment efficacy.
• Dietary supplements and repurposed drugs may induce apoptosis in RMS cells.

Conclusions:

• Targeting the PI3K-Akt-mTOR pathway is crucial for improving Rhabdomyosarcoma treatment.
• Innovative strategies, including targeting super-enhancers and transcription factors, are needed.
• Further research into targeted therapies holds promise for better patient outcomes in RMS.